Chronic Myeloid Leukemia (CML): What's Blood Got To Do With It?

This video describes what chronic myeloid leukemia (CML) is and discusses the following:

1. How CML occurs and what are its underlying mechanisms
2. Statistics regarding CML
3. Current treatments and their effectiveness

This video was made by Health Science 4DM3 students Khaled Nawar, Peter Tso, Salina Pasit and Ojan Yarkhani.

Copyright McMaster University 2018.

References:

1) Sawyers, C. L. (1999). Chronic myeloid leukemia. New England Journal of Medicine, 340(17), 1330-1340.

2) O'brien, S. G., Guilhot, F., Larson, R. A., Gathmann, I., Baccarani, M., Cervantes, F., ... & Lechner, K. (2003). Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. New England Journal of Medicine, 348(11), 994-1004.

3) Hehlmann, R., Hochhaus, A., & Baccarani, M. (2007). Chronic myeloid leukaemia. The Lancet, 370(9584), 342-350.

4) Druker, B. J., Sawyers, C. L., Kantarjian, H., Resta, D. J., Reese, S. F., Ford, J. M., ... & Talpaz, M. (2001). Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. New England Journal of Medicine, 344(14), 1038-1042.

5) Noens, L., Van Lierde, M. A., De Bock, R., Verhoef, G., Zachée, P., Berneman, Z., ... & De Geest, S. (2009). Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood, 113(22), 5401-5411.